Greg Silvanouve's questions to EyePoint Pharmaceuticals Inc (EYPT) leadership • Q2 2025
Question
Sam on behalf of Greg Silvanouve at Mizuho asked about the physician feedback received at the recent ASRS meeting and what incremental data to expect from the full end-of-study VORONNA data presentation in September.
Answer
CEO Jay Duker described the feedback at ASRS as 'incredible' and 'positive,' with physicians excited about the new mechanism of action and the potential for a true six-month treatment extension. CMO Ramiro Ribeiro stated that the upcoming VORONNA presentation will build on previously shared data regarding BCVA, CST, and treatment burden, but did not disclose further specifics ahead of the meeting.